Monthly Oncology Tumor Boards: Systemic Therapy Selection in Metastatic Castration-Resistant Prostate Cancer
The selection of systemic treatments in various lines of therapy for patients with metastatic castration-resistant prostate cancer (CRPC) has become more and more complicated over the last several years. Reasons for this increasing complexity include the growing number of systemic therapy options, specific biomarker requirements for some newer therapies, recent data that inform the optimal sequence for delivery of certain agents, and the contemporary use of some options (e.g., novel hormone therapies) in earlier stages of disease that alter what is appropriate in this later stage. Clinicians who work with patients with metastatic CRPC need to be educated on all of these points so that they can help their patients make optimal treatment choices across lines of therapy.
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Describe the role of tumor testing for homologous recombination gene mutations and microsatellite instability or mismatch repair deficiency in treatment selection for patients with metastatic castration-resistance prostate cancer (CRPC).
- Summarize recent data that informs sequencing of therapies in patients with metastatic CRPC.
- Discuss the rationale behind recent updates to the NCCN Guidelines for Prostate Cancer.
Andrew J. Armstrong, MD, ScM
Duke Cancer Institute
Joshua M. Lang, MD, MS
University of Wisconsin Carbone Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Andrew J. Armstrong, MD, ScM
Amgen Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Consulting Fee; Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Bayer HealthCare: Consulting Fee; Grant/Research Support
BeiGene: Grant/Research Support
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support
Clovis Oncology: Consulting Fee
Constellation Pharmaceuticals: Grant/Research Support
Dendreon Corporation: Consulting Fee; Grant/Research Support
Forma Therapeutics: Consulting Fee; Grant/Research Support
Merck & Co., Inc.: Consulting Fee; Grant/Research Support
Pfizer Inc.: Consulting Fee; Grant/Research Support
Joshua M. Lang, MD, MS
4D Pharma PLC: Consulting Fee
Astellas Pharma US, Inc.: Consulting Fee
Immunomedics, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
Salus Discovery, LLC: Equity Interest/Stock Options
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-21-042-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00047000; Approval #: 210002371
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
This webinar was presented live one time only on Wednesday, July 21, 2021, from 3:00 – 4:00 PM EDT (UTC -4). Click here to access the recorded webcast.
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing